

**AD-A276 531**



AD \_\_\_\_\_

(2)

MIPR NO: 93MM3578

**TITLE: VACCINE-INDUCED ENHANCEMENT OF EIAV REPLICATION  
AND DISEASE**

**PRINCIPAL INVESTIGATOR: Ronald C. Montelaro, Ph.D.**

**CONTRACTING ORGANIZATION:** University of Pittsburgh  
School of Medicine  
Department of Molecular  
Genetics & Biochemistry  
W1144 Biomedical Science Tower  
Pittsburgh, Pennsylvania 15261

**REPORT DATE:** January 14, 1994

**TYPE OF REPORT:** Final Report

**PREPARED FOR:** U.S. Army Medical Research and  
Development Command, Fort Detrick  
Frederick, Maryland 21702-5012

**DISTRIBUTION STATEMENT:** Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are  
those of the author(s) and should not be construed as an official  
Department of the Army position, policy or decision unless so  
designated by other documentation.

DTIC  
ELECTE  
FEB 28 1994  
S A

WPJ 94-06440



DTIC QUALITY INSPECTED 2

94 2 25 164

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average one hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports (DS-1), Jefferson Davis Highway, Suite 204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project O-124-0188, Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)			2. REPORT DATE	3. REPORT TYPE AND DATES COVERED	
			14 January 1994	Final Report (6/15/93 - 12/31/93)	
4. TITLE AND SUBTITLE			5. FUNDING NUMBERS		
Vaccine-Induced Enhancement of EIAV Replication and Disease			MIPR No. 93MM3578		
6. AUTHOR(S)			8. PERFORMING ORGANIZATION REPORT NUMBER		
Ronald C. Montelaro, Ph.D.					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)			9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)		
University of Pittsburgh School of Medicine Department of Molecular Genetics & Biochemistry W1144 Biomedical Science Tower Pittsburgh, Pennsylvania 15261			U.S. Army Medical Research & Development Command Fort Detrick Frederick, Maryland 21702-5012		
10. SPONSORING / MONITORING AGENCY REPORT NUMBER			11. SUPPLEMENTARY NOTES		
12a. DISTRIBUTION / AVAILABILITY STATEMENT			12b. DISTRIBUTION CODE		
Approved for public release; distribution unlimited					
13. ABSTRACT (Maximum 200 words)			The purpose of this funding was to initiate the expansion of ongoing research in which the equine infectious anemia virus (EIAV)/Shetland pony animal lentivirus system is being used as a model for human AIDS vaccines with respect to the elucidation of the mechanisms of vaccine enhancement, the evaluation of <u>in vitro</u> enhancement assays as correlates of <u>in vivo</u> enhancement, and the development of vaccination strategies that minimize the potential for deleterious immune responses. The current funding was specifically provided as a supplement to expand isolation facilities for housing EIAV-infected ponies, for the purchase of additional ponies to be used in vaccine trials, and for the production and biochemical characterization of recombinant protein vaccine, rgp90. All of these objectives have now been accomplished in anticipation of additional funding that will facilitate more detailed studies of vaccine-induced enhancement of EIAV replication and disease.		
14. SUBJECT TERMS			15. NUMBER OF PAGES		
AIDS vaccines, equine infectious anemia virus, vaccine enhancement, antibody dependent enhancement			16. PRICE CODE		
17. SECURITY CLASSIFICATION OF REPORT		18. SECURITY CLASSIFICATION OF THIS PAGE		19. SECURITY CLASSIFICATION OF ABSTRACT	
Unclassified		Unclassified		Unclassified	
20. LIMITATION OF ABSTRACT					
Unlimited					

FOREWORD

Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

**RCM** Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

**RCM** In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) have adhered to policies of applicable Federal Law 32 CFR 219 and Subparts B, C, and D.

**RCM** In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

**RCM** In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

**RCM** In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

*RC Montalvo* 14 Jan 94  
Principal Investigator's Signature Date

## Table of Contents

Introduction .....	1
Body .....	2
Conclusions .....	2
References .....	2-3
Appendices .....	n/a

Accession for	
NTIS	SP-871
DTIC	TAB
Unpublished	
Jurisdiction	
By	
Distribution /	
Available Codes	
Dist	Printed or Special
A-1	

## A. Introduction

The United States Army is currently involved in the design and evaluation of potential AIDS vaccines based on the use of selected HIV-1 antigens produced in various recombinant expression systems. Among the most thoroughly studied candidate AIDS vaccine is a baculovirus-expressed HIV-1 envelope glycoprotein, designated gp160 (Koff et al. 1990). This gp160 vaccine is being considered for human trials in Thailand under the auspices of the US Army.

However, there remains significant controversy regarding the potential efficacy of the gp160 vaccine based on initial limited human trials and additional concerns have been raised about the potential for eliciting deleterious immune responses that could result in a greater susceptibility to HIV-1 infection or an enhancement of virus replication and disease (Burke 1992). Vaccine-induced enhancement of viral infections has been documented in several viral systems, including dengue virus, respiratory syncytial virus, and feline infectious peritonitis virus (Porterfield 1986). In many of these cases, the enhancement phenomenon can be correlated with the presence of antibodies that bind to virus and enhance infection of target cells, especially monocytes and macrophages. Since monocytic cells are a primary target in all natural lentivirus infections, including HIV-1 infection of humans, the potential for antibody dependent enhancement (ADE) of HIV-1 infection and disease in humans needs to be considered carefully.

Enhancing antibodies have been demonstrated in vitro in serum from HIV-1 infected individuals (Robinson et al. 1988, Homsy et al. 1989), SIV-infected macaques (Montefiori et al. 1990), visna virus-infected sheep (Jolly et al. 1989), and CAEV-infected goats (McGuire et al. 1986). The potential role of enhancing antibodies in the development of AIDS has also been suggested, although the in vivo relevance of ADE remains uncertain and controversial (Homsy et al. 1990). To date there has been not reliable in vivo model to examine the mechanisms of ADE of lentivirus infections or to evaluate the prognostic value of in vitro assays of ADE.

In previous studies using the equine infectious anemia virus (EIAV)/Shetland pony system as a model for evaluating AIDS vaccine strategies, we have demonstrated a range of efficacy from sterile protection against homologous virus challenge by inactivated whole virus vaccines and viral envelope subunit vaccines, to severe enhancement of EIAV replication and disease in ponies immunized with a baculovirus-expressed envelope glycoprotein vaccine designated rgp90 (Issel et al. 1992, Wang et al. 1994). These vaccine trial suggest that immune responses to EIAV vaccine can elicit either protection against or enhancement of EIAV replication and disease, thus providing a novel in vivo model for characterizing both host and viral determinants associated with vaccine-induced protection and enhancement of a lentivirus

infection.

The use of EIAV as a model for evaluating potential strategies for AIDS vaccine development is an ongoing program funded by the National Institutes of Health. However, the objectives of this NIH funding are to characterize the immune correlates of protection that evolve naturally during persistent EIAV infection of ponies and to evaluate vaccine strategies for eliciting protective immune responses. To expand the studies to examining the recently discovered enhancement phenomenon, funding was requested and provided by the US Army by means of a one time supplement to the current NIH grant via interagency transfer. The specific objectives of the supplemental funding were: (i) construct 14 isolation stalls for housing EIAV-infected ponies, (ii) to purchase 16 ponies dedicated to vaccine enhancement studies, and (iii) to produce and characterize baculovirus-expressed EIAV gp90 to be used as vaccine in proposed enhancement studies. These preparations were in anticipation of funding of a pending grant application to the US Army (932110044) to facilitate a detailed study of EIAV vaccine enhancement that would begin in January 1994.

#### B. Body

As of December 31, 1993 we have completed the construction of dedicated isolation stalls at the University of Kentucky for housing ponies to be used in the EIAV enhancement studies. In addition, we have purchased 16 Shetland ponies for use in future experiments and are in the process of preparing these animals for use in the near future. At the University of Pittsburgh we have completed the preparation and standard characterizations of a stock of baculovirus rgp90 to be used in the planned vaccine trials.

#### C. Conclusions

As a result of the supplemental funding received in 1993, we are now poised to initiate extensive EIAV vaccine enhancement studies as soon as the pending application with the US Army is finalized. We have recently evaluated the rgp90 vaccine stock in a 4 pony pilot immunization trial and demonstrated a vaccine-induced enhancement of EIAV replication and disease, as reported in earlier trials (Wang et al., 1994).

#### D. References

- Burke, D. (1992) Perspect. Biol. Med. 35: 511-530.  
Homsy, J., Meyer, M. and Levy, J. (1990) J. Virol. 64: 1437-1440.  
Homsy, J., Tateno, M., and Levy, J. (1989) Science 244: 1357-1360.

Issel, C., Horovhov, D., Lea, D., Adams, W., Haguis, S., McManus, J., Allison, A., and Montelaro, R. (1992) *J. Virol.* **66**: 3398-3408.

Jolly, P., Huso, D., Sheffer, D., and Narayan, O. (1989) *J. Virol.* **63**: 1811-1813.

Koff, W., Wescott, S., and Hoth, D. (1990) In: "AIDS Vaccine Research and Clinical Trials" (S. Putney and D. Bolognesi, eds.), pp. 425-439, Dekker, New York.

McGuire, T., Adams, D., Johnson, G., Klevjer-Anderson, P., Barbee, P., and Gorham, J. (1986) *Am. J. Vet. Res.* **47**: 537-540.

Montefiori, D., Murphey-Corb, M., Desrosiers, R., and Daniel, M. (1990) *J. Virol.* **64**: 5223-5225.

Robinson, W., Montefiori, D., and Mitchell, W. (1988) *Lancet* **i**: 790-794.